RMR Wealth Builders Has $2.34 Million Stock Position in Merck & Co., Inc. (NYSE:MRK)

RMR Wealth Builders raised its stake in Merck & Co., Inc. (NYSE:MRK) by 5.4% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 21,456 shares of the company’s stock after purchasing an additional 1,095 shares during the quarter. RMR Wealth Builders’ holdings in Merck & Co., Inc. were worth $2,339,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently modified their holdings of MRK. Bare Financial Services Inc bought a new position in shares of Merck & Co., Inc. during the fourth quarter valued at about $28,000. Rakuten Securities Inc. bought a new stake in Merck & Co., Inc. in the 4th quarter worth approximately $30,000. RIA Advisory Group LLC bought a new stake in shares of Merck & Co., Inc. during the 4th quarter valued at $30,000. Ruedi Wealth Management Inc. boosted its holdings in Merck & Co., Inc. by 180.2% in the 3rd quarter. Ruedi Wealth Management Inc. now owns 311 shares of the company’s stock worth $32,000 after buying an additional 200 shares during the period. Finally, AlphaMark Advisors LLC purchased a new stake in Merck & Co., Inc. in the 4th quarter worth $34,000. 76.07% of the stock is owned by institutional investors.

Insider Buying and Selling at Merck & Co., Inc.

In other news, insider Joseph Romanelli sold 1,000 shares of Merck & Co., Inc. stock in a transaction dated Tuesday, February 13th. The shares were sold at an average price of $124.89, for a total transaction of $124,890.00. Following the completion of the sale, the insider now directly owns 19,569 shares in the company, valued at $2,443,972.41. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 0.09% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on MRK shares. TheStreet downgraded shares of Merck & Co., Inc. from a “b+” rating to a “c+” rating in a research note on Monday, March 4th. Truist Financial boosted their target price on shares of Merck & Co., Inc. from $142.00 to $143.00 and gave the stock a “buy” rating in a research note on Friday, April 26th. Barclays boosted their target price on shares of Merck & Co., Inc. from $135.00 to $145.00 and gave the company an “overweight” rating in a report on Friday, February 2nd. StockNews.com upgraded shares of Merck & Co., Inc. from a “buy” rating to a “strong-buy” rating in a report on Friday, February 2nd. Finally, Societe Generale lowered shares of Merck & Co., Inc. from a “hold” rating to a “sell” rating and set a $104.00 target price on the stock. in a report on Monday, March 11th. One investment analyst has rated the stock with a sell rating, three have given a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Merck & Co., Inc. has a consensus rating of “Moderate Buy” and an average price target of $131.33.

Merck & Co., Inc. Stock Down 0.0 %

Shares of NYSE MRK opened at $129.49 on Thursday. The company has a quick ratio of 1.00, a current ratio of 1.25 and a debt-to-equity ratio of 0.89. Merck & Co., Inc. has a 52 week low of $99.14 and a 52 week high of $133.10. The firm has a 50-day moving average price of $126.45 and a 200 day moving average price of $117.33. The stock has a market capitalization of $327.97 billion, a price-to-earnings ratio of 143.87, a price-to-earnings-growth ratio of 1.63 and a beta of 0.39.

Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings data on Thursday, April 25th. The company reported $2.07 EPS for the quarter, beating the consensus estimate of $1.94 by $0.13. Merck & Co., Inc. had a net margin of 3.76% and a return on equity of 14.15%. The firm had revenue of $15.78 billion during the quarter, compared to analysts’ expectations of $15.21 billion. During the same quarter last year, the business earned $1.40 earnings per share. The business’s revenue for the quarter was up 8.9% compared to the same quarter last year. Equities research analysts anticipate that Merck & Co., Inc. will post 8.69 EPS for the current fiscal year.

Merck & Co., Inc. Company Profile

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.